Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- TPST
- Price
- 7.15
- Stock movement up
- +6.65 (1328.29%)
- Company name
- Tempest Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 312.04M
- Ent value
- 312.30M
- Price/Sales
- -
- Price/Book
- 27.24
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -62.84%
- 1 year return
- 79.20%
- 3 year return
- 22.92%
- 5 year return
- -37.12%
- 10 year return
- -50.37%
Last updated: 2025-04-10
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
TPST does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 27.24 |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 43.64M |
| EPS (TTM) | -1.38 |
| FCF per share (TTM) | -1.14 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -328.00K |
| Operating income (TTM) | -35.62M |
| Net income (TTM) | -35.52M |
| EPS (TTM) | -1.38 |
| EPS (1y forward) | -1.10 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 22.12M |
| Net receivables | 0.00 |
| Total current assets | 23.55M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 33.84M |
| Accounts payable | 1.70M |
| Short/Current long term debt | 17.74M |
| Total current liabilities | 13.97M |
| Total liabilities | 22.38M |
| Shareholder's equity | 11.46M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -29.05M |
| Capital expenditures (TTM) | 439.00K |
| Free cash flow (TTM) | -29.49M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -310.01% |
| Return on Assets | -104.97% |
| Return on Invested Capital | -170.85% |
| Cash Return on Invested Capital | -141.86% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 6.38 |
| Daily high | 7.72 |
| Daily low | 5.99 |
| Daily Volume | 183K |
| All-time high | 12028.50 |
| 1y analyst estimate | 18.75 |
| Beta | -2.78 |
| EPS (TTM) | -1.38 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 7 May 2025 |
Downside potential
Loading...
Downside potential data
| TPST | S&P500 | |
| Current price drop from All-time high | -99.94% | -10.49% |
| Highest price drop | -100.00% | -56.47% |
| Date of highest drop | 9 Oct 2023 | 9 Mar 2009 |
| Avg drop from high | -81.73% | -11.07% |
| Avg time to new high | 78 days | 12 days |
| Max time to new high | 2528 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
312.04M
Marketcap category
Small-cap
Description
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. The company has agreement with Roche to advance the evaluation of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq®) and bevacizumab. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
Employees
17
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page